197 related articles for article (PubMed ID: 25258166)
1. Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition.
Krummel T; Garnon J; Lang H; Gangi A; Hannedouche T
BMC Urol; 2014 Sep; 14():77. PubMed ID: 25258166
[TBL] [Abstract][Full Text] [Related]
2. Laparoscopic cryoablation of angiomyolipomas in adolescents and young adults: A report of four cases associated with tuberous sclerosis and 1 case of sporadic origin.
Trelborg K; Nielsen TK; Østraat EØ; Olsen LH
J Pediatr Urol; 2016 Dec; 12(6):384.e1-384.e6. PubMed ID: 27346068
[TBL] [Abstract][Full Text] [Related]
3. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
[TBL] [Abstract][Full Text] [Related]
4. Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.
Hatano T; Egawa S
Asian J Surg; 2020 Oct; 43(10):967-972. PubMed ID: 31959574
[TBL] [Abstract][Full Text] [Related]
5. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
Krischock L; Beach R; Taylor J
Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
[TBL] [Abstract][Full Text] [Related]
8. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
9. Pediatric Renal Angiomyolipomas in Tuberous Sclerosis Complex.
Warncke JC; Brodie KE; Grantham EC; Catarinicchia SP; Tong S; Kondo KL; Cost NG
J Urol; 2017 Feb; 197(2):500-506. PubMed ID: 27678300
[TBL] [Abstract][Full Text] [Related]
10. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
Coombs EJ
J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
[TBL] [Abstract][Full Text] [Related]
11. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition.
Kronick J; Gabril MY; House AA
Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078
[TBL] [Abstract][Full Text] [Related]
12. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.
Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA
Nephron; 2016; 134(2):51-58. PubMed ID: 27504842
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
14. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.
Davies DM; de Vries PJ; Johnson SR; McCartney DL; Cox JA; Serra AL; Watson PC; Howe CJ; Doyle T; Pointon K; Cross JJ; Tattersfield AE; Kingswood JC; Sampson JR
Clin Cancer Res; 2011 Jun; 17(12):4071-81. PubMed ID: 21525172
[TBL] [Abstract][Full Text] [Related]
16. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease.
Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N
Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395
[TBL] [Abstract][Full Text] [Related]
17. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm Can Be Offered Active Surveillance as an Initial Management Strategy.
Bhatt JR; Richard PO; Kim NS; Finelli A; Manickavachagam K; Legere L; Evans A; Pei Y; Sykes J; Jhaveri K; Jewett MAS
Eur Urol; 2016 Jul; 70(1):85-90. PubMed ID: 26873836
[TBL] [Abstract][Full Text] [Related]
18. Giant renal angiomyolipoma in a solitary kidney.
Sohlberg E; Sun A; Massoudi R; Prado K; Skinner E
Can J Urol; 2018 Dec; 25(6):9614-9616. PubMed ID: 30553288
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex.
Barnett JR; Grinspoon RA; Harisinghani M; Caruso PA; Thiele EA
J Clin Neurosci; 2020 Jul; 77():85-88. PubMed ID: 32409220
[TBL] [Abstract][Full Text] [Related]
20. Update on the Diagnosis and Management of Renal Angiomyolipoma.
Flum AS; Hamoui N; Said MA; Yang XJ; Casalino DD; McGuire BB; Perry KT; Nadler RB
J Urol; 2016 Apr; 195(4 Pt 1):834-46. PubMed ID: 26612197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]